Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With Heart Failure and Left Ventricular Systolic Dysfunction

NCT01786512 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.

NCT NCT01786512
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01786512 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With Heart Failure and Left Ventricular Systolic Dysfunction
Lead sponsor
Cytokinetics
Phase
Phase 2
Overall status
Completed
Start date
February 26, 2013
Completion date
August 19, 2015
Enrollment
544 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure, echocardiogram, history of chronic heart failure, left ventricular ejection fraction, left ventricular systolic dysfunction, modified release oral formulation, pharmacokinetics